Limits...
Smoking cessation therapy with varenicline.

Mohanasundaram UM, Chitkara R, Krishna G - Int J Chron Obstruct Pulmon Dis (2008)

Bottom Line: Varenicline is a novel agent that is a centrally acting partial nicotinic acetylcholine receptor agonist.It has both agonistic and antagonistic properties that together are believed to account for reduction of craving and withdrawal as well as blocking the rewarding effects of smoking.Its targeted mechanism of action, better efficacy and tolerability makes varenicline a useful therapeutic option for smoking cessation.

View Article: PubMed Central - PubMed

Affiliation: Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, CA, USA.

ABSTRACT
Smoking cessation is the only available intervention proven to halt progression of chronic obstructive pulmonary disease (COPD). The authors discuss the current existing treatment modalities and the role of a newly approved agent, varenicline, in promotion of smoking cessation. Varenicline is a novel agent that is a centrally acting partial nicotinic acetylcholine receptor agonist. It has both agonistic and antagonistic properties that together are believed to account for reduction of craving and withdrawal as well as blocking the rewarding effects of smoking. Its targeted mechanism of action, better efficacy and tolerability makes varenicline a useful therapeutic option for smoking cessation. In this article, we discuss presently available options for smoking cessation and review the literature on efficacy of varenicline.

Show MeSH

Related in: MedlinePlus

Varenicline tartrate (7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino [2,3-h][3]benzazepine).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2629973&req=5

f3-copd-3-239: Varenicline tartrate (7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino [2,3-h][3]benzazepine).

Mentions: Varenicline (7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine) is a partial agonist selective for the α4β2 nicotinic acetylcholine receptor subtype (Figure 3). This tartrate salt is highly soluble in water, with a molecular weight of 361.35 Da (Zieler-Brown and Kyle 2007).


Smoking cessation therapy with varenicline.

Mohanasundaram UM, Chitkara R, Krishna G - Int J Chron Obstruct Pulmon Dis (2008)

Varenicline tartrate (7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino [2,3-h][3]benzazepine).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2629973&req=5

f3-copd-3-239: Varenicline tartrate (7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino [2,3-h][3]benzazepine).
Mentions: Varenicline (7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine) is a partial agonist selective for the α4β2 nicotinic acetylcholine receptor subtype (Figure 3). This tartrate salt is highly soluble in water, with a molecular weight of 361.35 Da (Zieler-Brown and Kyle 2007).

Bottom Line: Varenicline is a novel agent that is a centrally acting partial nicotinic acetylcholine receptor agonist.It has both agonistic and antagonistic properties that together are believed to account for reduction of craving and withdrawal as well as blocking the rewarding effects of smoking.Its targeted mechanism of action, better efficacy and tolerability makes varenicline a useful therapeutic option for smoking cessation.

View Article: PubMed Central - PubMed

Affiliation: Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, CA, USA.

ABSTRACT
Smoking cessation is the only available intervention proven to halt progression of chronic obstructive pulmonary disease (COPD). The authors discuss the current existing treatment modalities and the role of a newly approved agent, varenicline, in promotion of smoking cessation. Varenicline is a novel agent that is a centrally acting partial nicotinic acetylcholine receptor agonist. It has both agonistic and antagonistic properties that together are believed to account for reduction of craving and withdrawal as well as blocking the rewarding effects of smoking. Its targeted mechanism of action, better efficacy and tolerability makes varenicline a useful therapeutic option for smoking cessation. In this article, we discuss presently available options for smoking cessation and review the literature on efficacy of varenicline.

Show MeSH
Related in: MedlinePlus